Media Release

Basel, 20 February 2007

Roche and GSK agree on two transactions

• Roche to out-license orlistat non-prescription rights to GSK beyond US
• Roche and GSK to settle all arbitration procedures related to carvedilol

Roche has granted GlaxoSmithKline Consumer Healthcare an exclusive license for the non-prescription rights to its anti-obesity medicine orlistat in non-US countries excluding Japan. Roche retains all worldwide rights for the prescription version of orlistat and continues to market it under the brand name Xenical 120 mg. The transaction follows the agreement in July 2004 where Roche already out-licensed the US non-prescription rights to orlistat 60 mg to GSK. Roche will receive an upfront payment. The financial terms are not disclosed. Roche will support GSK with supply during an initial period.

"Roche has gained a top-tier partner in pursuing a successful OTC brand based on our prescription medicine Xenical," said William M. Burns, CEO Roche Pharma. "Given the strong expertise in the consumer health business, we believe that GSK will maximize the potential of this effective weight loss drug in the non-prescription area."

In a separate transaction both companies agreed to settle all arbitration procedures between the two companies relating to the licensing and co-marketing of carvedilol. As part of this settlement agreement, Roche will make an undisclosed payment to GSK, for which sufficient financial provisions have already been made.

About Roche
Headquartered in Basel, Switzerland, Roche is one of the world’s leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As a supplier of innovative products and services for the early detection, prevention, diagnosis and treatment of diseases, the Group contributes on a broad range of fronts to improving people’s health and quality of life. Roche is a world leader in diagnostics, the leading supplier of drugs for cancer and transplantation and a market leader in virology. In 2006 sales by the Pharmaceuticals Division totalled 33.3 billion Swiss francs, and the Diagnostics Division posted sales of 8.7 billion Swiss francs. Roche employs roughly 75,000 people in 150 countries and has R&D agreements and strategic alliances with numerous partners, including majority ownership interests in Genentech and Chugai. Additional information about the Roche Group is available on the Internet at www.roche.com.

All trademarks used or mentioned in this release are protected by law.